Sesen Bio, Inc. is a clinical-stage biotechnology company that is focused on developing fusion protein therapeutics to treat cancer patients. The lead program of the company is known as Vicinium and is presently in a Phase 3 registration trial for non-muscle invasive bladder cancer. Vicinium employs an anti-EpCAM antibody fragment that is attached to a truncated form of Pseudomonas Exotoxin A to target high-risk NMIBC. The company has initiated the BLA submission process for Vicinium to the FDA under Rolling Review.
Sesen Bio's ticker is SESN
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 11-50 employees working at Sesen Bio
It is sesenbio.com/about
Sesen Bio is in the Healthcare sector
Sesen Bio is in the Biotechnology industry
The following five companies are Sesen Bio's industry peers: